Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Eupraxia Pharmaceuticals Inc's Competitiveness

Name: Eupraxia Pharmaceuticals Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Eupraxia Pharmaceuticals Inc (EPRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/EPRX/competitors                    

                        https://api.csimarket.com/api/v1/companies/EPRX/relationships                    

                        https://api.csimarket.com/api/v1/companies/EPRX/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Eupraxia Pharmaceuticals Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Eupraxia Pharmaceuticals Inc	-	-	-	No
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

EPRX Stock Performance relative to its Competitors

EPRX Competitors (weighted) Percent change over the selected range

Eupraxia Pharmaceuticals Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Similar-Size
(3 of 10)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Eupraxia Pharmaceuticals Inc	42.20 %	Outperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (10)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Eupraxia Pharmaceuticals Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

EPRX Stock Performance relative to Similar-Size Competitors

EPRX Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Eupraxia Pharmaceuticals Inc's Comment on Competition and Industry Peers

The company operates in a competitive environment with numerous competitors that may possess greater resources and significant investments in competing technologies. Some competitors have obtained patents that could restrict or prevent the company from making, using, or selling its potential product candidates. The patent landscape presents uncertainties, including risks of patents being challenged, invalidated, or circumvented. Additionally, governmental pressures exist to limit patent protections for successful treatments, and foreign patent laws may be less favorable, potentially enabling foreign competitors to develop and market competing products.

Competitor data is not yet available for Eupraxia Pharmaceuticals Inc.